1872 related articles for article (PubMed ID: 26830752)
1. Pancreatic cancer.
Kamisawa T; Wood LD; Itoi T; Takaori K
Lancet; 2016 Jul; 388(10039):73-85. PubMed ID: 26830752
[TBL] [Abstract][Full Text] [Related]
2. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
3. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
4. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
7. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
El Rassy E; Assi T; El Karak F; Ghosn M; Kattan J
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e26-e28. PubMed ID: 28215539
[No Abstract] [Full Text] [Related]
8. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
9. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
10. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data.
Singhi AD; Zeh HJ; Brand RE; Nikiforova MN; Chennat JS; Fasanella KE; Khalid A; Papachristou GI; Slivka A; Hogg M; Lee KK; Tsung A; Zureikat AH; McGrath K
Gastrointest Endosc; 2016 Jun; 83(6):1107-1117.e2. PubMed ID: 26709110
[TBL] [Abstract][Full Text] [Related]
11. The role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms.
; Muthusamy VR; Chandrasekhara V; Acosta RD; Bruining DH; Chathadi KV; Eloubeidi MA; Faulx AL; Fonkalsrud L; Gurudu SR; Khashab MA; Kothari S; Lightdale JR; Pasha SF; Saltzman JR; Shaukat A; Wang A; Yang J; Cash BD; DeWitt JM
Gastrointest Endosc; 2016 Jul; 84(1):1-9. PubMed ID: 27206409
[No Abstract] [Full Text] [Related]
12. [FOLFIRINOX, nab-paclitaxel + gemcitabine].
Shimizu S
Nihon Rinsho; 2015 Mar; 73 Suppl 3():405-8. PubMed ID: 25857057
[No Abstract] [Full Text] [Related]
13. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609
[TBL] [Abstract][Full Text] [Related]
14. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
[TBL] [Abstract][Full Text] [Related]
15. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
17. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Ghosn M; Ibrahim T; Assi T; El Rassy E; Kourie HR; Kattan J
World J Gastroenterol; 2016 Dec; 22(46):10124-10130. PubMed ID: 28028360
[TBL] [Abstract][Full Text] [Related]
18. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Vaccaro V; Sperduti I; Milella M
N Engl J Med; 2011 Aug; 365(8):768-9; author reply 769. PubMed ID: 21864184
[No Abstract] [Full Text] [Related]
20. Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Singapore Cancer Network (SCAN) Pancreatic Cancer Workgroup
Ann Acad Med Singap; 2015 Oct; 44(10):388-96. PubMed ID: 26763056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
